Company Update

Norris Medicines confirmed its compliance regarding share dematerialisation for the quarter ended June 2025. The company's Registrar and Transfer Agent certified that all requests for converting physical shares to electronic form were properly processed, accepted, or rejected.

This ensures share certificates were cancelled and records updated efficiently.

This update highlights the company's commitment to maintaining accurate shareholder records and smooth operational processes for investors.